Jill Feldman: EGFR Resisters is becoming an independent 501(c)(3) non-profit organization
Jill Feldman, Co-Founder of EGFR Resisters and Lung Cancer Patient and Advocate shared a post on X:
“Big News!
EGFR Resisters is becoming an independent 501(c)(3) non-profit organization!
Since 2017, we’ve united a global community of 6,000+ patients and caregivers, raised over $1M for research, and created essential resources for those impacted by EGFR-positive lung cancer. Now, we’re ready to achieve even more.
As we move forward, we honor our founding members – Teri Kennedy, Ivy Elkins, Ildiko Medve, Anita Figueras, and Allen Lee—whose vision and spirit continue to inspire us.
Learn more about what’s next here.
Support our mission here.”
Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder of EGFR Resisters, an advocacy group of EGFR-positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board, and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, a planning committee member on IASLC’s North America Conference on Lung Cancer, and a member of the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.
More posts featuring Jill Feldman.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023